Changes in Hong Kong stocks | Goodwill B (02256) rose nearly 8% in the intraday ABSK061 phase II clinical study received positive initial efficacy results

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that Heyu-B (02256) rose nearly 8% intraday. As of press release, it rose 7.05% to HK$8.88, with a turnover of HK$10.425,600.

According to the news, Heyu announced that a phase II clinical study of the selective oral small molecule FGFR2/3 inhibitor lavenGratinib (ABSK061) by the company's subsidiary, to treat achondroplasia in children received positive initial curative results.

Zhongtai Securities recently released a research report to adjust Heyu's profit forecast, mainly by adjusting the pace of revenue recognition for milestones related to pimitinib licensing based on the company's revenue situation in the first half of 2026, without changing the core pipeline and BD value implementation logic. The new multi-asset cooperation further proves the advancement of the company's technology platform. As core assets continue to advance and subsequent milestones and cooperation values are gradually released, the company's medium- to long-term growth logic is clear, maintaining a “buy” rating.